Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE

Antibody Persistence in 11 to 13-year-old Children Previously Vaccinated at 6 Years Old With Either REVAXIS or DT Polio, and Immune Response to a Booster Dose of TETRAVAC-ACELLULAIRE

PRIMARY OBJECTIVES

• To describe in 11 to 13-year-old children previously vaccinated with either REVAXIS or DT Polio at 6 years of age the antibody persistence against diphtheria, tetanus, and poliovirus types 1, 2 and 3
• To describe one month after a booster dose of TETRAVAC-ACELLULAIRE the immune responses against diphtheria, tetanus, and poliovirus types 1, 2 and 3

SECONDARY OBJECTIVES

• To describe other parameters of the antibody persistence against diphtheria, tetanus and poliomyelitis antigens
• To describe other parameters of the immune responses to diphtheria, tetanus and poliomyelitis antigens one month after a booster dose of TETRAVAC-ACELLULAIRE
• To describe the safety profile of a booster dose of TETRAVAC-ACELLULAIRE

Inclusion Criteria:

• Healthy child 11 to 13 years of age previously vaccinated in Study F05-TdI-301

Exclusion Criteria:

• Immunization against diphtheria, tetanus, pertussis and/or poliomyelitis beyond Study F05-TdI-301
• Previous clinical or bacteriological diagnosis of diphtheria, tetanus, pertussis or poliomyelitis
• Known or suspected immune dysfunction
• Receipt of medications / vaccination that may interfere with study assessments
• Known true hypersensitivity to any of the vaccine components or to a vaccine containing the same substances
• Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition
• Thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection
• Any medical condition that might interfere with the evaluation of the study objectives
• Febrile illness